Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Total Assets : $12.49 Mil (As of Dec. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Eucrates Biomedical Acquisition Total Assets?

Eucrates Biomedical Acquisition's Total Assets for the quarter that ended in Dec. 2022 was $12.49 Mil.

During the past 12 months, Eucrates Biomedical Acquisition's average Total Assets Growth Rate was -88.10% per year.

Total Assets is connected with ROA %. Eucrates Biomedical Acquisition's annualized ROA % for the quarter that ended in Dec. 2022 was 0.96%. Total Assets is also linked to Revenue through Asset Turnover. Eucrates Biomedical Acquisition's Asset Turnover for the quarter that ended in Dec. 2022 was 0.00.

Eucrates Biomedical Acquisition Total Assets Historical Data

The historical data trend for Eucrates Biomedical Acquisition's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eucrates Biomedical Acquisition Total Assets Chart

Eucrates Biomedical Acquisition Annual Data

Trend

Dec20

Dec21

Dec22

Total Assets

105.83

105.11

12.49

Eucrates Biomedical Acquisition Quarterly Data
	Aug20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Total Assets	Get a 7-Day Free Trial					105.11	105.18	105.18	105.52	12.49

Eucrates Biomedical Acquisition Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Eucrates Biomedical Acquisition's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Assets	=	Total Equity (A: Dec. 2022 )	+	Total Liabilities (A: Dec. 2022 )
	=	8.536	+	3.95
	=	12.49

Eucrates Biomedical Acquisition's Total Assets for the quarter that ended in Dec. 2022 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2022 )	+	Total Liabilities (Q: Dec. 2022 )
	=	8.536	+	3.95
	=	12.49

Eucrates Biomedical Acquisition (NAS:EUCRU) Total Assets Explanation

Total Assets is connected with ROA %.

Eucrates Biomedical Acquisition's annualized ROA % for the quarter that ended in Dec. 2022 is

ROA %	=	Net Income (Q: Dec. 2022 )	/	( (Total Assets (Q: Sep. 2022 )	+	Total Assets (Q: Dec. 2022 ))	/ count )
	=	0.568	/	( (105.516	+	12.485)	/ 2 )
	=	0.568	/	59.0005
	=	0.96 %

Note: The Net Income data used here is four times the quarterly (Dec. 2022) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Eucrates Biomedical Acquisition's Asset Turnover for the quarter that ended in Dec. 2022 is

	Asset Turnover
=	Revenue (Q: Dec. 2022 )	/	( (Total Assets (Q: Sep. 2022 )	+	Total Assets (Q: Dec. 2022 ))	/ count )
=	0	/	( (105.516	+	12.485)	/ 2 )
=	0	/	59.0005
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Eucrates Biomedical Acquisition Total Assets Related Terms

Thank you for viewing the detailed overview of Eucrates Biomedical Acquisition's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Eucrates Biomedical Acquisition Corp (NAS:EUCRU) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

250 West 55th Street, Suite 13D, New York, NY, USA, 10019

Website

Eucrates Biomedical Acquisition Corp is a blank check company.

Executives

Stelios Papadopoulos	director, 10 percent owner	3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020
William I Campbell	director	270 PARK AVENUE, NEW YORK NY 10017
Nina B. Shapiro	director	2201 WALNUT AVENUE, SUITE 100, FREMONT CA 94538
Parag Saxena	director, 10 percent owner, officer: Chief Executive Officer	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Daphne Karydas	director	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Atanuu Agarrwal	officer: Vice President	250 WEST 55TH STREET, NEW YORK NY 10019
Gonzalo Cordova	officer: Chief Financial Officer	250 WEST 55TH STREET, NEW YORK NY 10019
Eucrates Llc	10 percent owner	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Shrikant Sathe	officer: Senior Vice President	C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Evangelos Vergetis	director, officer: President, COO	C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Amitabh Singhal	director	C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Headlines

From GuruFocus

Eucrates Biomedical Acquisition Corp. Receives Expected Notice From Nasdaq Regarding Delayed Quarterly Report

By PRNewswire PRNewswire • 06-01-2021

Eucrates Biomedical Acquisition Corp. Announces Closing Of $100 Million Initial Public Offering

By PRNewswire PRNewswire • 10-28-2020

Eucrates Biomedical Acquisition Corp. Announces Liquidation

By PRNewswire PRNewswire • 04-11-2023